CGRP-driven neuromodulation and therapies that block CGRP or its receptor - can modulate thalamic activity and reduce the sensory hypersensitivity underlying photophobia and other migraine symptoms (Schulte and May, 2017; Tu et al., 2016; Ziegeler et al., 2020). The gene discussed is CALCA; the disease is Photophobia.